NYSEARCA:THNR Amplify Weight Loss Drug & Treatment ETF (THNR) Price, Holdings, & News $27.19 +0.19 (+0.70%) Closing price 09/3/2026 04:10 PM EasternExtended Trading$27.19 +0.00 (+0.01%) As of 04:01 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisChartDividendHoldingsOwnershipRatings About Amplify Weight Loss Drug & Treatment ETF (NYSEARCA:THNR) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get THNR alerts:Sign Up Key Stats Today's Range$26.97▼$27.3150-Day Range$25.29▼$27.9152-Week Range$22.63▼$27.94Volume801 shsAverage Volume2,057 shsMarket Capitalization$5.44 millionAssets Under Management$5.39 millionDividend YieldN/ANet Expense Ratio0.59%Aggregate RatingModerate Buy ETF Overview The Amplify Weight Loss Drug & Treatment ETF (THNR) is an exchange-traded fund that is based on the VettaFi Weight Loss Drug index. The fund tracks a modified market cap-weighted index of companies from developed markets that manufacture and enable GLP-1 agonist pharmaceutical businesses. THNR was launched on May 21, 2024 and is issued by Amplify Investments. Read More Amplify Weight Loss Drug & Treatment ETF ExpensesTypeTHNRTheme ETFsEquity ETFsNYSEARCA ETFsAll ETFsManagement Fee0.59%0.57%0.57%0.50%0.53%Other Expenses0.00%0.57%0.53%0.60%0.54%Total Expense0.59%0.72%0.75%0.75%0.73%Fee Waiver0.00%-0.72%-0.67%-0.78%-0.68%Net Expense0.59%0.60%0.63%0.57%0.60% Receive THNR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Amplify Weight Loss Drug & Treatment ETF and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. THNR ETF News HeadlinesETFs tied to HIMS gain attention as the telehealth stock spikesMarch 9, 2026 | msn.comHims & Hers, Eli Lilly, Novo Nordisk Face FDA Scrutiny: What It Means For Weight-Loss ETFsSeptember 18, 2025 | benzinga.comThree companies about to leapfrog Nvidia [And transform the entire industry]In 1984, a 10000 dollar stake in Apple could have grown to 25 million dollars for early investors who simply got in before the Macintosh launch. Tech analyst George Gilder says a similar setup is forming today, but instead of one company, he points to three that he calls the Trillion Dollar Triangle. Gilder argues these three companies represent connected pieces of one major shift rather than competitors racing for the same outcome. | Eagle Publishing (Ad)Why Investors Haven't Feasted on Two New Weight-Loss ETFsJune 24, 2024 | investopedia.comSee More Headlines THNR ETF - Frequently Asked Questions How have THNR shares performed this year? Amplify Weight Loss Drug & Treatment ETF's stock was trading at $25.22 at the start of the year. Since then, THNR shares have increased by 7.8% and is now trading at $27.19. How do I buy shares of Amplify Weight Loss Drug & Treatment ETF? Shares of THNR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Amplify Weight Loss Drug & Treatment ETF own? Based on aggregate information from My MarketBeat watchlists, some other companies that Amplify Weight Loss Drug & Treatment ETF investors own include Archer Aviation (ACHR), Advanced Micro Devices (AMD), Beam Therapeutics (BEAM), CRISPR Therapeutics (CRSP), Lockheed Martin (LMT), NiCE (NICE) and Intellia Therapeutics (NTLA). Fund Details IssuerAmplify Fund NameAmplify Weight Loss Drug & Treatment ETF Tax ClassificationRegulated Investment Company Stock ExchangeNYSEARCACurrent SymbolNYSEARCA:THNR Inception Date5/21/2024 Fund ManagerDustin Lewellyn, Ernesto Tong, Anand Desai WebN/A PhoneN/AFund Focus Asset ClassEquity BenchmarkN/A CategoryStrategy FocusTheme Development LevelDeveloped Markets RegionGlobal Number of Holdings23 Fund Statistics Assets Under Management$5.39 million Average Daily Volume$0.00 Discount/Premium0.07% Administrator, Advisor and Custodian AdministratorU.S. Bancorp Fund Services, LLC AdvisorAmplify Investments, LLC CustodianU.S. Bank, N.A. DistributorForeside Fund Services, LLC Transfer AgentU.S. Bancorp Fund Services, LLC TrusteeN/A Lead Market MakerGTS Miscellaneous Outstanding Shares200,000Beta0.39 Creation Unit10,000 Creation Fee$300.00 7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free Report Top 10 THNR HoldingsNovo Nordisk A/S (NYSE:NVO)Holding Weight: 9.25%Eli Lilly and Company (NYSE:LLY)Holding Weight: 9.08%Regeneron Pharmaceuticals (NASDAQ:REGN)Holding Weight: 6.13%Innovent Biologics, Inc.Holding Weight: 5.85%CSPC Pharmaceutical Group LimitedHolding Weight: 5.54%Amgen (NASDAQ:AMGN)Holding Weight: 5.48%Scholar Rock (NASDAQ:SRRK)Holding Weight: 5.36%Arrowhead Pharmaceuticals (NASDAQ:ARWR)Holding Weight: 5.19%Roche Holding AGHolding Weight: 5.11%Merck & Co., Inc. (NYSE:MRK)Holding Weight: 5.07%Full Holdings DetailsTHNR Sector ExposureTHNR Industry Exposure This page (NYSEARCA:THNR) was last updated on 9/4/2026 by MarketBeat.com Staff. From Our PartnersRickards Predicts: Trump to buy tiny $2 stock?Jim Rickards believes the Trump administration is about to take a direct stake in a $2 stock sitting on the la...Paradigm Press | SponsoredA weekly dividend fund holding Nvidia and PalantirCrowdStrike, Palantir, Nvidia none of them pay a real dividend. But one fund holding the biggest AI names dist...Investors Alley | SponsoredInside the site of Elon’s next major breakthroughInside an ordinary Fremont, California building, Elon Musk is reportedly developing technology he says could e...Monument Traders Alliance | SponsoredThree companies about to leapfrog Nvidia [And transform the entire industry]AI data centers have a power problem nobody likes to talk about. A single rack of computers can now use more e...Eagle Publishing | SponsoredChina's Weapon Vanished From U.S. RadarChina reportedly flew a hypersonic weapon around the globe and U.S. radar couldn't track it. Now the Pentagon ...Freedom Financial | SponsoredThis walnut-sized chunk could pay your salary through Labor Day NEXT YEAR, however …A walnut-sized chunk of gold today is worth about what the average American earns in a year. In 1971, that sam...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Amplify Weight Loss Drug & Treatment ETF Please log in to your account or sign up in order to add this asset to your watchlist. Share Amplify Weight Loss Drug & Treatment ETF With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
